Overview

• Participants receiving biweekly TPE combined with IVIG saw an average reduction of 2.61 years in biological age, nearly double the 1.32-year decrease observed with TPE alone.
• Multi-omics profiling across epigenomic, proteomic, metabolomic, glycomic and immune markers confirmed significant rejuvenation effects after the initial three treatment sessions.
• Cellular senescence-associated proteins decreased and age-linked shifts in immune cell composition reversed, indicating restored immune resilience.
• Individuals with elevated baseline biomarkers for poor health—such as bilirubin, glucose and liver enzymes—experienced the most pronounced age-reversal responses.
• Study leaders from Circulate Health and the Buck Institute plan to expand the trial to larger populations to assess long-term efficacy and optimize treatment intervals.